Vai al contenuto principale della pagina
| Autore: |
Tagit Oya
|
| Titolo: |
Nanomedicine Formulations Based on PLGA Nanoparticles for Diagnosis, Monitoring and Treatment of Disease: From Bench to Bedside
|
| Pubblicazione: | Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022 |
| Descrizione fisica: | 1 online resource (296 p.) |
| Soggetto topico: | History of engineering and technology |
| Materials science | |
| Technology: general issues | |
| Soggetto non controllato: | 3D culture |
| amine | |
| angiotensin | |
| animal model | |
| anti-inflammatory | |
| antigen release | |
| atorvastatin calcium | |
| biocompatible | |
| biodegradable | |
| blood-brain barrier (BBB) | |
| brightness | |
| cancer | |
| cardiovascular | |
| carrageenan induced inflammation | |
| central nervous system | |
| chemoimmunotherapy | |
| chitosan | |
| clinical translation | |
| confocal microscopy | |
| coumarin 6 | |
| current Good Manufacturing Practice (cGMP) | |
| Cy5.5 | |
| cytotoxicity | |
| design of experiments | |
| DiI | |
| double emulsion solvent evaporation | |
| double-emulsion method | |
| downstream processing | |
| drug delivery | |
| drug delivery system | |
| drug release | |
| drug release kinetics modeling | |
| dry powder inhalation | |
| emulsion | |
| encapsulation | |
| ester and acid-end capped | |
| fluorescent labeling | |
| Food and Drug Administration (FDA) | |
| H. pylori | |
| immune checkpoint blockade | |
| immunogenic cell death | |
| in vitro | |
| in vivo neuroimaging | |
| Indomethacin | |
| inline sonication | |
| intracellular internalization | |
| JO-4 | |
| Katushka | |
| lyophilization | |
| mas receptor | |
| methotrexate | |
| micro-implant | |
| microfluidic | |
| microfluidics | |
| minimally invasive | |
| morphology | |
| nanomedicine | |
| nanoparticle | |
| nanoparticles | |
| nanotechnology | |
| neurodegenerative diseases | |
| neuroprotective drugs | |
| nuclear medicine | |
| orthotopic tumors | |
| particle-size | |
| PEGylation | |
| pharmacokinetics (PK) and biodistribution | |
| photothermal therapy | |
| phthalocyanine | |
| PLA/PLGA | |
| PLGA | |
| PLGA diblock copolymer | |
| PLGA nanoparticles | |
| Pluronic triblock copolymer | |
| PNA5 glycopeptide | |
| poly (lactic-co-glycolic acid) (PLGA) | |
| poly(lactic-co-glycolic acid) | |
| poly(lactic-co-glycolic acid) (PLGA) | |
| poly(lactic-co-glycolic) acid | |
| poly(lactide-co-glycolide) | |
| polymeric nanoparticles | |
| polyvinyl alcohol (PVA) | |
| porous PLGA particles | |
| quantum yield | |
| radiolabeled nanoparticles | |
| rhodamine 123 | |
| scale-up manufacturing | |
| size | |
| SKOVip-kat | |
| solid-state characterization | |
| solvents | |
| spheroids | |
| stability of fluorescent label | |
| stabilizers | |
| sucrose | |
| sustained release | |
| tangential flow filtration | |
| trehalose | |
| TurboFP635 | |
| Persona (resp. second.): | TagitOya |
| Sommario/riassunto: | Nanomedicine is among the most promising emerging fields that can provide innovative and radical solutions to unmet needs in pharmaceutical formulation development. Encapsulation of active pharmaceutical ingredients within nano-size carriers offers several benefits, namely, protection of the therapeutic agents from degradation, their increased solubility and bioavailability, improved pharmacokinetics, reduced toxicity, enhanced therapeutic efficacy, decreased drug immunogenicity, targeted delivery, and simultaneous imaging and treatment options with a single system.Poly(lactide-co-glycolide) (PLGA) is one of the most commonly used polymers in nanomedicine formulations due to its excellent biocompatibility, tunable degradation characteristics, and high versatility. Furthermore, PLGA is approved by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for use in pharmaceutical products. Nanomedicines based on PLGA nanoparticles can offer tremendous opportunities in the diagnosis, monitoring, and treatment of various diseases.This Special Issue aims to focus on the bench-to-bedside development of PLGA nanoparticles including (but not limited to) design, development, physicochemical characterization, scale-up production, efficacy and safety assessment, and biodistribution studies of these nanomedicine formulations. |
| Altri titoli varianti: | Nanomedicine Formulations Based on PLGA Nanoparticles for Diagnosis, Monitoring and Treatment of Disease |
| Titolo autorizzato: | Nanomedicine Formulations Based on PLGA Nanoparticles for Diagnosis, Monitoring and Treatment of Disease: From Bench to Bedside ![]() |
| Formato: | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione: | Inglese |
| Record Nr.: | 9910580215803321 |
| Lo trovi qui: | Univ. Federico II |
| Opac: | Controlla la disponibilità qui |